U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Triad Rx, Inc. - 569659 - 05/03/2023
  1. Warning Letters

CLOSEOUT LETTER

Triad Rx, Inc. MARCS-CMS 569659 —

Delivery Method:
Via Electronic Mail Return Confirmation Requested
Product:
Drugs
Recipient:
Recipient Name
Matt McDonald
Recipient Title
Owner
Triad Rx, Inc.

26258 Pollard Rd.
Daphne, AL 36526-4250
United States

Issuing Office:
Division of Pharmaceutical Quality Operations II

United States

Dear Mr. McDonald:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL 569659 Issued February 5, 2019]. We acknowledge that your firm no longer produces sterile drug products.

Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Ronda R. Loyd-Jones
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top